The FDA decision on Novo Nordisk’s (NVO) supplemental NDA for once-weekly Ozempic injection 0.5 mg or 1 mg is expected on January 20, 2020.The Company is pursuing an indication to reduce the risk of major adverse cardiovascular events (MACE) such as heart attack, stroke, or death in adults with type 2 diabetes and established cardiovascular disease. Ozempic, a glucagon-like peptide-1 (GLP-1) analog administered once-weekly, secured its initial FDA approval on December 5, 2017, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.Sales of Ozempic were 1,796 million Danish kroner ($266 million) for full-year 2018, and DKK 6,872 million ($1 billion) in the first nine months of 2019.NVO closed Monday’s (Dec.30, 2019) trading at $57.73, down 0.91%.